Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Pegram

Showing results (31-40 of 39) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 39 results.
Elife|March 27, 2024
Conformation selection by ATP-competitive inhibitors and allosteric communication in ERK2Jake W Anderson, David Vaisar, David N Jones, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2001
Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancerG Konecny, M Untch, J Arboleda, et al.
The New England Journal of Medicine|March 15, 2001
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2D J Slamon, B Leyland-Jones, S Shak, et al.
Applied and Environmental Microbiology|December 8, 2005
Application of stereolithographic custom models for studying the impact of biofilms and mineral precipitation on fluid flowD L Stoner, S M Watson, R D Stedtfeld, et al.
Blood|February 1, 1988
The correlation of breakpoint cluster region rearrangement and p210 phl/abl expression with morphological analysis of Ph-negative chronic myeloid leukemia and other myeloproliferative diseasesL M Wiedemann, K K Karhi, M K Shivji, et al.
Biochemical Pharmacology|February 13, 2001
Enzyme-catalyzed therapeutic agent (ECTA) design: activation of the antitumor ECTA compound NB1011 by thymidylate synthaseD B Lackey, M P Groziak, M Sergeeva, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 18, 2019
Activation loop dynamics are controlled by conformation-selective inhibitors of ERK2Laurel M Pegram, Jennifer C Liddle, Yao Xiao, et al.
International Journal of Cancer|December 15, 1986
Ethnic composition, age and sex, together with location and standard of housing as determinants of HLTV-I infection in an urban Trinidadian communityG J Miller, S M Pegram, B R Kirkwood, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 26, 2021
Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysisG Curigliano, V Mueller, V Borges, et al.
Pageof 4

Showing results (31-40 of 39) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 39 results.
Elife|March 27, 2024
Conformation selection by ATP-competitive inhibitors and allosteric communication in ERK2Jake W Anderson, David Vaisar, David N Jones, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 8, 2001
Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancerG Konecny, M Untch, J Arboleda, et al.
The New England Journal of Medicine|March 15, 2001
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2D J Slamon, B Leyland-Jones, S Shak, et al.
Applied and Environmental Microbiology|December 8, 2005
Application of stereolithographic custom models for studying the impact of biofilms and mineral precipitation on fluid flowD L Stoner, S M Watson, R D Stedtfeld, et al.
Blood|February 1, 1988
The correlation of breakpoint cluster region rearrangement and p210 phl/abl expression with morphological analysis of Ph-negative chronic myeloid leukemia and other myeloproliferative diseasesL M Wiedemann, K K Karhi, M K Shivji, et al.
Biochemical Pharmacology|February 13, 2001
Enzyme-catalyzed therapeutic agent (ECTA) design: activation of the antitumor ECTA compound NB1011 by thymidylate synthaseD B Lackey, M P Groziak, M Sergeeva, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 18, 2019
Activation loop dynamics are controlled by conformation-selective inhibitors of ERK2Laurel M Pegram, Jennifer C Liddle, Yao Xiao, et al.
International Journal of Cancer|December 15, 1986
Ethnic composition, age and sex, together with location and standard of housing as determinants of HLTV-I infection in an urban Trinidadian communityG J Miller, S M Pegram, B R Kirkwood, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 26, 2021
Tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB): final overall survival analysisG Curigliano, V Mueller, V Borges, et al.
Pageof 4